Dr. Robert Prins' research group studies immune-based therapies for the treatment of malignant glioma. Despite recent advances in traditional treatment options, the prognosis for these patients has not changed appreciably in twenty years. Thus, these patients are left with few treatment options. Members of Prins' research group are attempting to apply what they learn from pre-clinical models towards the implementation of immunotherapy clinical trials for brain tumor patients. This work is truly “translational” in nature and straddles the boundary between clinical medicine and basic research. On one hand, Prins' group spends a significant amount of time trying to understand the mechanisms by which tumor-specific T-cells can be activated to target tumor cells in the brain. On the other hand, Prins leads the laboratory effort for immunotherapy clinical trials at UCLA in glioma patients; in this aspect, he generates dendritic cell vaccines for these patients. This work represents the “bench to bedside” philosophy and truly is an active synergy between laboratory and clinical medicine.
Selected Cancer-Related Publications:
Fong B, Jin R, Wang X, Safaee M, Lisiero DN, Yang I, Li G, Liau LM, Prins RM. Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. PLoS One. 2012 Apr 2;7(4):e32614.
Lisiero DN, Soto H, Liau LM, Prins RM. Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8(+) T cells in a melanoma model. J Immunol. 2011 May 1;186(9):5068-77. Epub 2011 Mar 23
Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, Nelson SF, Liau LM, Konkankit V. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011 Mar 15;17(6):1603-15. Epub 2010 Dec 6
Konkankit VV, Kim W, Koya RC, Eskin A, Dam MA, Nelson S, Ribas A, Liau LM, Prins RM. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway. J Transl Med. 2011 Nov 7;9:192.
Prins RM, Cloughesy TF, Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med. 2008 Jul 31;359(5):539-41.